ES2056054T3 - Uso de linfocitos t activados para preparar una composicion farmaceutica para el tratamiento del sida. - Google Patents

Uso de linfocitos t activados para preparar una composicion farmaceutica para el tratamiento del sida.

Info

Publication number
ES2056054T3
ES2056054T3 ES87113709T ES87113709T ES2056054T3 ES 2056054 T3 ES2056054 T3 ES 2056054T3 ES 87113709 T ES87113709 T ES 87113709T ES 87113709 T ES87113709 T ES 87113709T ES 2056054 T3 ES2056054 T3 ES 2056054T3
Authority
ES
Spain
Prior art keywords
lymphocytes
activated
aids
aids virus
infected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87113709T
Other languages
English (en)
Inventor
Shiu-Lok Hu Ph D
Joyce Zarling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Application granted granted Critical
Publication of ES2056054T3 publication Critical patent/ES2056054T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE LINFOCITOS T ACTIVADOS A UNA DOSIS EFECTIVA PARA TRANSFERIR INMUNIDAD CELULAR INTERVENIDA CONTRA CELULAS INFECTADAS CON EL VIRUS DEL SIDA; A) LOS LINFOCITOS T ACTIVADOS SON ESPECIFICOS PARA UN EPITOPE DEL VIRUS DEL SIDA Y SON HISTOCOMPATIBLES CON EL PACIENTE; Y B) LOS LINFOCITOS T SON CAPACES DE INTERVENIR LA INMUNIDAD DE CELULA T ESPECIFICA DEL VIRUS DEL SIDA, SEGUN SE VE EN LOS SIGUIENTES ENSAYOS: (I) UN ENSAYO DE CITOTOXICIDAD EN EL QUE LOS LINFOCITOS T ACTIVADOS ESTAN INCUBADOS CON LAS CELULAS OBJETIVO DEL PACIENTE MARCADAS RADIACTIVAMENTE INFECTADAS CON EL VIRUS DEL SIDA, SIENDO LA LIBERACION DE LA MARCA RADIACTIVA LA SEÑAL DE LISIS DE LAS CELULAS OBJETIVO INFECTADAS; Y (II) UN ENSAYO DE ESTIMULACION QUE MIDE LA POSIBILIDAD DE LOS LINFOCITOS T ACTIVADOS DE PROLIFERAR Y/O PRODUCIR UNA LINFOQUINA EN RESPUESTA A LA ESTIMULACION CON UN EPITOPE DEL VIRUS DEL SIDA IN VITRO PARA PREPARAR UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DEL SIDA.
ES87113709T 1986-09-19 1987-09-18 Uso de linfocitos t activados para preparar una composicion farmaceutica para el tratamiento del sida. Expired - Lifetime ES2056054T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90944786A 1986-09-19 1986-09-19

Publications (1)

Publication Number Publication Date
ES2056054T3 true ES2056054T3 (es) 1994-10-01

Family

ID=25427241

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87113709T Expired - Lifetime ES2056054T3 (es) 1986-09-19 1987-09-18 Uso de linfocitos t activados para preparar una composicion farmaceutica para el tratamiento del sida.

Country Status (5)

Country Link
EP (1) EP0260714B1 (es)
JP (2) JPS63119428A (es)
AT (1) ATE107861T1 (es)
DE (1) DE3750151T2 (es)
ES (1) ES2056054T3 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2914889A (en) * 1987-08-28 1989-04-17 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
AU2925789A (en) * 1987-12-17 1989-07-19 Browning's Clinical Pathology Services Limited Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
CA2089488A1 (en) * 1990-09-06 1993-03-07 Judy Lieberman Pathogen-specific ctl therapy
DE4422020A1 (de) * 1993-07-29 1995-02-02 Bernhard Heising Pharmazeutische Zusammensetzung
AU7386094A (en) * 1993-07-29 1995-02-28 Bernhard Heising T-lymphocyte-containing pharmaceutical composition for treating infections
ES2203782T3 (es) * 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
EP2406387A4 (en) * 2009-03-09 2013-04-17 Tvax Biomedical I Llc CELL IMMUNOTHERAPY FOR INFECTION DISEASES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930000189B1 (ko) * 1984-10-18 1993-01-11 앵스뛰띠 빠스뙤르 임파선증과 후천성 면역 결핍증 바이러스의 항원을 제조하는 방법 및 이 항원에 대한 항체의 생산 방법
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
FR2593189B1 (fr) * 1986-01-22 1989-10-20 Pasteur Institut Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
FR2593190B1 (fr) * 1986-01-22 1989-10-20 Pasteur Institut Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida

Also Published As

Publication number Publication date
EP0260714B1 (en) 1994-06-29
JPS63119428A (ja) 1988-05-24
DE3750151D1 (de) 1994-08-04
EP0260714A2 (en) 1988-03-23
JPH08308563A (ja) 1996-11-26
EP0260714A3 (en) 1988-08-24
DE3750151T2 (de) 1994-12-01
ATE107861T1 (de) 1994-07-15

Similar Documents

Publication Publication Date Title
ES2054693T3 (es) Compuestos antivirales.
ES2097748T3 (es) Uso de derivados funcionales de la molecula de adhesion intercelular icam-1 en la terapia antivirica.
ES2050668T3 (es) Composiciones que mejoran la permeabilidad de la piel con el uso de monolaurato de glicerol.
MX169646B (es) Aparato para supervisar la presion sanguinea de un cuerpo
EP0252962A4 (en) Regulating retroviral replication, infection, and pathogenesis
ES2179105T3 (es) Adyuvantes proteinicos.
TR199903053T2 (xx) Benzimidazol t�revleri.
FI20001231A7 (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
ES2186714T3 (es) Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
MX9303597A (es) Derivados de imidazopirinas, procedimiento para su preparacion preparaciones farmaceuticas que los contienen.
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
ES2070276T3 (es) Lactonas macrociclicas inhibidoras del crecimiento celular denominadas combretastatina d-2.
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
ES2054716T3 (es) Bis-naftalimidas, su obtencion y empleo.
ES2061453T3 (es) Composiciones farmaceuticas antivirales que contienen hipericina o pseudohipericina.
SE8406538D0 (sv) Novel derivatives of purine
DK0879056T3 (da) Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter
ES2056054T3 (es) Uso de linfocitos t activados para preparar una composicion farmaceutica para el tratamiento del sida.
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
ES2105684T3 (es) Derivados insaturados de fosfonato de purinas y pirimidinas.
ES432696A1 (es) Procedimiento de preparacion de vacunas.
ES2064748T3 (es) Composiciones antiviricas conteniendo derivados del sulfoquinovosil glicerol y analogos del mismo y su uso.
ES2058252T3 (es) Arnasa l activada como marcador para infecciones viricas.
ES2036532T3 (es) Nucleosidos de isohexida, procedimientos para su preparacion y su uso como medicamentos.
ES2173453T3 (es) Nuevos dispositivos destinados a la administracion transdermica de trimegestona.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 260714

Country of ref document: ES